FDA 483 - PTC Therapeutics, Inc. - November 18, 2024

An FDA inspection of PTC Therapeutics, Inc. in Warren, NJ, revealed a failure to ensure proper monitoring of a clinical study. Specifically, site monitoring did not adequately identify and document discrepancies in investigational product accountability as protocol deviations for non-compliant subjects. This indicates issues with clinical trial oversight and data integrity.